Effects of dual blockade of renin-angiotensin system in type 2 diabetes mellitus patients with diabetic nephropathy

Journal of the Medical Association of Thailand

Volumn 92, Issue 5, 2009, Pages 611-617

  Krairittichai, Udom ^a   Chaisuvannarat, Viranya ^a  

^a RAJAVITHI HOSPITAL   (Thailand)

Author keywords

Angiotensin II type 1 receptor blockers; Angiotensin converting enzyme inhibitors; Diabetes mellitus; Diabetic nephropathies; Type 2

Indexed keywords

ENALAPRIL; TELMISARTAN;

ADULT; ANEMIA; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; COUGHING; CREATININE URINE LEVEL; DEATH; DIABETIC NEPHROPATHY; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG INHIBITION; DRUG MECHANISM; DRUG MEGADOSE; FEMALE; GLOMERULUS FILTRATION RATE; HOSPITAL ADMISSION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN URINE LEVEL; PROTEINURIA; RECOMMENDED DRUG DOSE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIDE EFFECT; THERAPY EFFECT; TREATMENT DURATION;

ADULT; AGED; ANALYSIS OF VARIANCE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BENZOATES; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ENALAPRIL; FEMALE; HUMANS; MALE; MIDDLE AGED; PROTEINURIA; RENIN-ANGIOTENSIN SYSTEM; TREATMENT OUTCOME;

EID: 66649094130     PISSN: 01252208     EISSN: 01252208     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Ritz E, Orth SR. Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med 1999; 341: 1127-1133 (Pubitemid 29466226)
2. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329: 1456-1462
3. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869
4. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860
5. Molitch ME, DeFronzo RA, Franz MJ, Keane WF, Mogensen CE, Parving HH. Diabetic nephropathy. Diabetes Care 2003; 26 (Suppl 1): S94-8. (Pubitemid 36928968)
6. Thurman JM, Schrier RW. Comparative effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on blood pressure and the kidney. Am J Med 2003; 114: 588-598 (Pubitemid 36577262)
7. Lebovitz HE, Wiegmann TB, Cnaan A, Shahinfar S, Sica DA, Broadstone V, et al. Renal protective effects of enalapril in hypertensive NIDDM: role of baseline albuminuria. Kidney Int Suppl 1994; 45: S150-5. (Pubitemid 24043617)
8. Bakris GL. Effects of diltiazem or lisinopril on massive proteinuria associated with diabetes mellitus. Ann Intern Med 1990; 112: 707-708 (Pubitemid 20137180)
9. Nielsen FS, Rossing P, Gall MA, Skott P, Smidt UM, Parving HH. Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. Diabetes 1997; 46: 1182-1188 (Pubitemid 27271080)
10. Fogari R, Zoppi A, Corradi L, Mugellini A, Lazzari P, Preti P, et al. Long-term effects of ramipril and nitrendipine on albuminuria in hypertensive patients with type II diabetes and impaired renal function. J Hum Hypertens 1999; 13: 47-53. (Pubitemid 29042145)
11. Cooper ME. Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet 1998; 352: 213-219
12. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-2572 (Pubitemid 37430158)
13. European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-1053
14. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878
15. American Diabetes Association. Diabetic nephropathy. Diabetes Care 2002; 25 (Suppl 1): S85-9.
16. Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW, et al. Randomised controlled trial of dual blockade of reninangiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000; 321: 1440-1444
17. Jacobsen P, Andersen S, Rossing K, Hansen BV, Parving HH. Dual blockade of the reninangiotensin system in type 1 patients with diabetic nephropathy. Nephrol Dial Transplant 2002; 17: 1019-1024 (Pubitemid 34746204)
18. Rossing K, Christensen PK, Jensen BR, Parving HH. Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study. Diabetes Care 2002; 25: 95-100. (Pubitemid 41070790)
19. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 3992 (Suppl 1): S1-266.
20. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470 (Pubitemid 29135798)
21. Rossing P. Promotion, prediction and prevention of progression of nephropathy in type 1 diabetes mellitus. Diabet Med 1998; 15: 900-919 (Pubitemid 28500243)
22. De Jong PE, Navis G, de Zeeuw D. Renoprotective therapy: titration against urinary protein excretion. Lancet 1999; 354: 352-353 (Pubitemid 29355744)
23. Ravid M, Lang R, Rachmani R, Lishner M. Longterm renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study. Arch Intern Med 1996; 156: 286-289 (Pubitemid 26058479)
24. Sano T, Kawamura T, Matsumae H, Sasaki H, Nakayama M, Hara T, et al. Effects of long-term enalapril treatment on persistent micro-albuminuria in well-controlled hypertensive and normotensive NIDDM patients. Diabetes Care 1994; 17: 420-424 (Pubitemid 24145216)
25. Ahmad J, Siddiqui MA, Ahmad H. Effective postponement of diabetic nephropathy with enalapril in normotensive type 2 diabetic patients with microalbuminuria. Diabetes Care 1997; 20: 1576-1581 (Pubitemid 27415037)
26. Jacobsen P, Andersen S, Jensen BR, Parving HH. Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy. J Am Soc Nephrol 2003; 14: 992-999 (Pubitemid 36359280)
27. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372: 547-553